Cancer diagnostics company (Nasdaq: GH)
Appears in 4 stories
Provider of the Guardant360 CDx companion diagnostic used in SERENA-6
For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.
Updated May 31
Key competitor to the combined Abbott/Exact Sciences entity
Abbott Laboratories closed its $21 billion acquisition of Exact Sciences on March 23, making the maker of the Cologuard colorectal cancer screening test a wholly owned subsidiary of one of the world's largest healthcare companies. The all-cash deal, at $105 per share, passed through antitrust review without a second request from regulators—a sign of how little the two companies' product lines overlapped before this combination.
Updated May 30
Developed FDA-approved blood screening test
Colorectal cancer now kills more Americans under 50 than any other cancer. James Van Der Beek, who played Dawson Leery in the late-1990s teen drama Dawson's Creek, died February 11 at age 48 after a 30-month battle with colorectal cancer. He became the latest public figure to put a face on an epidemic that medical guidelines have only recently begun to address.
Updated May 27
Maker of the newly approved Guardant360 Liquid CDx
For most patients with advanced cancer, picking the right targeted drug still starts with a tissue biopsy. On May 20, the FDA approved a blood test that reads 100 times more of the tumor's DNA than the previous version.
Updated May 20
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
